Highlighting the urgent need for enhanced diagnostics in leukemia, lymphoma, and myeloma.
MSInsight developed MSIcare to detect microsatellite instability (MSI) directly from NGS data — not only from tumor tissue, but even from a simple blood draw. This means no surgical biopsy required to get critical genomic data.
Why it matters:
- MSI testing can guide immunotherapy for blood cancer patients.
- Our mission is to bring precise, scalable diagnostics to more cancer types.
We’re standing with families and patients this month, rallying for greater awareness, innovation, and access to life-saving diagnostics.
Â
